Search

everythinglearnresearchcommunity

for

Search:↓

Adding antihistamines to topical corticosteroid and cryotherapy may improve hair regrowth in alopecia areata patients.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Higher CRBP1 levels are linked to more severe alopecia areata.

Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.

The excimer laser may help hair regrow in alopecia areata patients.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

The combination therapy of microdermabrasion and steroid injections is more effective for treating scalp Alopecia Areata than steroid injections alone.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Baricitinib is the most effective treatment for alopecia areata.

The combined therapy was effective and safe for children with severe alopecia areata.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

New treatment effectively reverses hair thinning in most patients with mild side effects.

An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.

Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

Guidelines help design better trials to compare alopecia areata treatments.

Botulinum toxin type A injections are not effective for severe alopecia areata.

Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.

Researchers had trouble finding enough participants for a trial on DHEA's effects on postmenopausal women's sexual desire.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.

Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Peripheral blood alive cell treatment is effective and safe for treating hair loss.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.